Castle Biosciences Inc (CSTL) — Strategic Asset Allocation Index
Castle Biosciences Inc (CSTL) has a Strategic Asset Allocation Index of 1.3% as of March 2025. Strategic assets (PP&E of $- plus long-term investments of $5.57 Million) total $5.57 Million, measured against net assets of $440.31 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check CSTL cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Castle Biosciences Inc Strategic Asset Allocation Index (2019–2022)
This chart shows how Castle Biosciences Inc's Strategic Asset Allocation Index has evolved across 4 annual periods from 2019 to 2022. As of March 2025, the index stands at 1.3%, representing strategic assets of $5.57 Million against net assets of $440.31 Million USD. See Castle Biosciences Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Castle Biosciences Inc (2019–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Castle Biosciences Inc from 2019 to 2022, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is Castle Biosciences Inc worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 6.6% | $26.50 Million | $26.50 Million | $- | $399.15 Million | ▲ +2.5 pp |
| 2021 | 4.1% | $16.88 Million | $16.88 Million | $- | $411.74 Million | ▲ +2.4 pp |
| 2020 | 1.7% | $7.10 Million | $7.10 Million | $- | $415.69 Million | ▼ -0.7 pp |
| 2019 | 2.4% | $2.06 Million | $2.06 Million | $- | $85.11 Million | — |